Glenmark Pharmaceuticals Receives FDA Approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution

Glenmark Pharmaceuticals Ltd. has received final approval from the U.S. Food & Drug Administration (FDA) for its Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%. According to IQVIATM sales data, the market for the referenced Combigan® Ophthalmic Solution achieved annual sales of approximately $290.0 million. This approval adds to Glenmark's existing portfolio of 196 products in the U.S. marketplace and 51 ANDA's pending approval.